د. منال موسي الهباش2024-12-042024-12-04https://dspace.academy.edu.ly/handle/123456789/500Objective: This study was conducted to achieve three main aims: (i) evaluating the cardiac effect of trastuzumab use among Libyan HER-2 + BC patients in clinical practice. (ii) assessing the incidence of TIC and CHF. (iii) identifying the possible risk factors that could induce cardiotoxicity among Libyan breast cancer patients who used the studied intervention.Background: Breast cancer remains a pervasive global health concern, and its heterogenous nature calls for tailored therapeutic approaches. Trastuzumab, a monoclonal antibody targeting HER2, has revolutionized the treatment landscape for HER2+ BC patients. It significantly improves the patients' survival rates. However, a well-documented concern with trastuzumab is its potential to induce cardiotoxicity, which present a significant challenge in clinical management.function in the treatment